Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Up 0.9% – Here’s Why

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) shot up 0.9% during trading on Wednesday. The stock traded as high as $1.18 and last traded at $1.15. 20,960 shares traded hands during trading, a decline of 76% from the average session volume of 86,732 shares. The stock had previously closed at $1.14.

Analysts Set New Price Targets

ACXP has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Acurx Pharmaceuticals in a report on Tuesday, September 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Acurx Pharmaceuticals presently has an average rating of “Hold”.

Acurx Pharmaceuticals Stock Performance

The stock has a market capitalization of $6.39 million, a price-to-earnings ratio of -0.43 and a beta of -2.05. The company has a 50 day moving average of $1.35 and a 200 day moving average of $1.68.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.15). As a group, research analysts expect that Acurx Pharmaceuticals, Inc. will post -2.00 EPS for the current fiscal year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on antibacterial compounds designed to address pathogens that are increasingly resistant to existing treatments.

Acurx’s lead product candidate is ibezapolstat, an investigational antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile or C.